Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

In vitro and in vivo bone anabolic effects of P2X7 receptor blocker AFC-5261

Sep. 18, 2014

Development of non-viral minicircle DNA vectors for phenylketonuria gene therapy

Sep. 18, 2014

Results for the follow-up portion of phase II study evaluating blosozumab

Sep. 17, 2014

Full results presented for SPARK study of sapropterin in infants with phenylketonuria

Sep. 17, 2014

Ultragenyx presents promising interim phase I/II results for rhGUS enzyme replacement therapy

Sep. 16, 2014

FDA advisory committee recommends approval of Natpara for hypoparathyroidism

Sep. 15, 2014

ViaCyte receives accelerated development pathway grant for VC-01

Sep. 15, 2014

FDA advisory committee recommends approval of liraglutide for obesity

Sep. 12, 2014

FDA approves Contrave for chronic weight management

Sep. 12, 2014

SRI International and Nobelpharma sign licensing agreement on SR-16234 for endometriosis

Sep. 12, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026